Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for rare metabolic genetic diseases, raised the price range for its upcoming IPO on Wednesday. The Novato, CA-based company now plans to raise $94 million by offering 4.8 million shares at a price range of $19 to $20, up from a range of $14 to $17. At the midpoint of the revised range, Ultragenyx Pharmaceutical will raise 26% more than previously anticipated. Ultragenyx Pharmaceutical, which was founded in 2010, plans to list on the NASDAQ under the symbol RARE. Ultragenyx Pharmaceutical initially filed confidentially on 10/4/2013. J.P. Morgan and Morgan Stanley are the joint bookrunners on the deal.
